Want to see NZ:CVT full AI Analyst Report?
Comvita (CVT) AI Stock Analysis
Comvita
(NZX:CVT)
The score is driven primarily by improved financial performance (profitability returning, strong operating/free cash flow, and materially better leverage). Valuation is supportive with a low P/E, but technicals are only neutral-to-soft in the near term, and the earnings call highlights meaningful uncertainties (no FY27 guidance yet, China pressure, and North America margin compression) that temper confidence in the durability of the recovery.
Comvita (CVT) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- NZD 30.05M
- Dividend Yield
- ―
- Average Volume (3M)
- 25.23K
- Price to Earnings (P/E)
- 7.6
- Beta (1Y)
- 1.16
- Revenue Growth
- 10.67%
- EPS Growth
- ―
- Country
- NZ
- Employees
- 395
- Sector
- Consumer Defensive
- Sector Strength
- 62
- Industry
- Packaged Foods
Comvita Business Overview & Revenue Model
Company Description
Comvita Limited, along with its associated entities, specializes in the global production and distribution of natural health products. The company boasts a significant international presence, operating across diverse markets in Australasia, Asia (inc...
Comvita Earnings Call Summary
The call emphasizes a clear recovery: the company returned to profitability, materially improved cash generation, substantially reduced net debt to a net cash position, normalized inventory and secured refinancing and a strategic investor. Commercially, North America and parts of Southeast Asia delivered strong growth, gross margins improved and operating costs were reduced. However, significant challenges remain — notably margin compression in North America, softer demand and pricing pressure in Greater China, outstanding overhead optimization, and near-term risks from harvest variability and geopolitical/market uncertainty. Overall, the positive financial repair and diversification progress materially outweigh the remaining challenges.
Q4-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Management gave no numeric FY‑27 guidance at the call — saying it is too early and that guidance will be provided once apiary crop and channel visibility improves (notably after November) — but framed a disciplined outlook underpinned by FY‑26 metrics: revenue of $213.0m, reported NPAT $7.7m, normalized EBIT $16.4m (vs prior guidance $15.5m) and operating profit $14.0m; operating cash flow of $40.3m and positive free cash flow; net debt turned from $62.4m to net cash $0.5m; inventory reduced from $89.0m to $79.9m (≈$80m target); gross margin recovered to 53.9% (vs a normalized FY‑25 50.8%); operating expenses were cut by $8m; North America sales rose to $58.7m (from $28.7m) though contribution margin fell 14.1%→6.6%, Greater China contribution margin is ~14%; capital raise issue costs were $3.42m with failed SIA costs ~$1.4m, refinancing provides covenant headroom to Sept 2028, and dividends will only resume when earnings, cash generation and balance sheet metrics sustainably support them.
Comvita Financial Statement Overview
Summary
FY26 shows a clear turnaround: revenue rose to 213.0M, gross margin improved to ~53.9%, the company returned to positive EBIT (~6.1% margin) and net income (~3.6% margin), operating cash flow was strong (~35.1M) with positive free cash flow (~33.8M), and leverage improved materially with debt reduced and debt-to-equity ~0.32. The main constraint is multi-year volatility (deep losses and negative FCF in 2022–2025), so durability of the recovery is still being proven.
Income Statement
62PositiveBalance Sheet
74PositiveCash Flow
69Positive| Breakdown | TTM | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 212.96M | 212.96M | 192.43M | 200.68M | 234.19M | 209.09M |
| Gross Profit | 114.80M | 114.80M | 82.70M | 108.88M | 135.76M | 126.23M |
| EBITDA | 21.61M | 21.99M | -14.62M | -63.03M | 31.78M | 30.56M |
| Net Income | 7.74M | 7.74M | -104.76M | -77.39M | 11.06M | 12.78M |
Balance Sheet | ||||||
| Total Assets | 164.88M | 164.88M | 173.35M | 307.86M | 358.77M | 332.78M |
| Cash, Cash Equivalents and Short-Term Investments | 13.00M | 13.00M | 9.00M | 8.16M | 11.55M | 17.76M |
| Total Debt | 30.54M | 30.54M | 91.70M | 109.42M | 80.30M | 56.10M |
| Total Liabilities | 68.06M | 68.06M | 118.45M | 147.23M | 119.45M | 104.79M |
| Stockholders Equity | 96.83M | 96.83M | 54.90M | 160.63M | 239.32M | 227.99M |
Cash Flow | ||||||
| Free Cash Flow | 33.84M | 33.84M | 30.89M | -2.19M | -18.04M | -5.87M |
| Operating Cash Flow | 35.10M | 35.10M | 34.14M | 5.33M | 2.40M | 3.58M |
| Investing Cash Flow | -1.45M | -1.45M | -1.66M | -13.65M | -20.79M | -13.22M |
| Financing Cash Flow | -30.31M | -30.31M | -31.65M | 5.04M | 12.46M | 10.88M |
Comvita Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NZ:CVT, the sentiment is Negative. The current price of 0.76 is below the 20-day moving average (MA) of 0.78, below the 50-day MA of 0.79, and above the 200-day MA of 0.71, indicating a neutral trend. The MACD of 0.00 indicates Positive momentum. The RSI at 41.85 is Neutral, neither overbought nor oversold. The STOCH value of 10.74 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for NZ:CVT.
Comvita Peers Comparison
Overall Rating
NZ:ATM69Neutral- NZ:CVT67Neutral
NZ:SAN66Neutral
NZ:NZK54Neutral
NZ:SML49Neutral
NZ:MEE40Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| NZ:ATM | 69Neutral | NZD 6.29B | 27.87 | 17.63% | 7.29% | 3.84% | 6.53% |
| NZ:CVT | 67Neutral | NZD 98.04M | 7.56 | 9.98% | ― | 10.67% | ― |
| NZ:SAN | 66Neutral | NZD 640.52M | 8.90 | 9.48% | 1.72% | -4.16% | 91.88% |
| Sector * | 62Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% |
| NZ:NZK | 54Neutral | NZD 129.16M | -13.64 | -4.98% | ― | ― | ― |
| NZ:SML | 49Neutral | NZD 310.65M | -4.24 | -10.58% | ― | -7.94% | -95.77% |
| NZ:MEE | 40Underperform | NZD 7.39M | -2.30 | ― | ― | -12.36% | 79.80% |
* Consumer Defensive Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| NZ:CVT | Comvita | 0.76 | 0.03 | 3.85% | |
| NZ:ATM | a2 Milk Company Ltd. | 8.64 | -1.57 | -15.39% | |
| NZ:NZK | New Zealand King Salmon Investments Ltd. | 0.24 | 0.04 | 20.00% | |
| NZ:SAN | Sanford | 6.85 | 0.80 | 13.15% | |
| NZ:SML | Synlait Milk Ltd. | 0.52 | -0.20 | -28.47% | |
| NZ:MEE | Me Today Limited | 0.07 | 0.00 | 0.00% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 05, 2026